- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01947569
Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy
Autologous Co-stimulation-impaired Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy: A Sequential Open Label Phase IB Safety Assessment/ Randomized, Double-blind Phase IIA Efficacy Trial to Maintain and Improve Functional Beta Cell Mass in New Onset Disease T1DM Patients
Phase IB will evaluate the safety of autologous, ex vivo-engineered, co-stimulation impaired dendtritic cells to maintain and improve functional residual beta cell mass in new onset Type I Diabetes Mellitus (T1DM) patients. Efficacy measures will be collected and summarized.
Phase IIA will evaluate the safety and efficacy of 3 randomized treatment groups in new onset T1DM patients to assess if the antisense DNA-treated co-stimulation-impaired immunoregulatory dendritic cells (iDC) will safely preserve and/or increase B-cell mass resulting in improvement and/or normalization of blood glucose levels and glycated hemoglobin A1c.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Orville G. Kolterman, MD
- Phone Number: 7242085707
- Email: okolterman@alumnistandford.edu
Study Contact Backup
- Name: Peter Gregoire, MBA
- Phone Number: 7242085707
- Email: pgregoire@futurelifesourcesllc.org
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- UPMC
-
Principal Investigator:
- Mary Korytokowski, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:(both open label phase IB safety and Phase IIA study):
- Patients with new onset T1DM (>18 years of age for the phase IB and then >16 (first 10 subjects), >12 years of age for the second 10 subjects, > 8 years for the next 10 subjects and, finally, >8 years of age for the remainder of the phase IIA patients) within 6 months of diabetes mellitus diagnosis.
- Evidence of decreased β-cell function as measured by C-peptide and blood glucose levels consistent with impaired glucose tolerance.
- Evidence of at least one high-risk HLA haplotype.
- Evidence of at least one diabetes-related autoantibody (e.g. IA-2, GAD, ZnT8) ,
- Adequate immune competence as assessed by immunoreactivity to alloantigens in mixed leukocyte culture and reactivity to viral antigens (CEF Pool Assay) in vitro.
- Normal hematologic, liver and kidney function.
- Female participants of childbearing potential in this study must agree to use an effective form of birth control during study participation. Reliable and effective forms of birth control include: true abstinence, intrauterine device (IUD), hormonal-based contraception, double-barrier contraception [condom or occlusive cap (diaphragm or cervical cap) with spermicide], or surgical sterilization (vasectomy for male partner, tubal ligation or hysterectomy). Sexually active male participants must agree to use an effective form of birth control such as condoms.
Exclusion Criteria:(both open label phase IB safety and Phase IIA study):
- Enrollment or history of enrollment in a drug, or biologic therapy study sponsored by TrialNet.
- A significant history or current evidence of cardiac disease, uncontrolled hypertension, serious arrhythmias.
- Evidence of active infection requiring antibiotic therapy.
- History of other concurrent significant medical diseases.
- Pregnant or lactating women.
- Patients requiring chronic systemic corticosteroids.
- Any other immune disorder including but not limited to other autoimmune diseases, HIV, HBV, HCV, HPV, HSV positivity.
- Impaired renal function with a creatinine level > 1.5.
- Administration of the following therapies while patients are undergoing treatment on this protocol: i) radiation therapy; ii) chemotherapy; iii) corticosteroids (except when administered in life-threatening circumstances); iv) other particle or cell-based therapies; v) other biologic therapies; vi) other therapies aimed at modulating the immune system; vii) other endocrine-related therapies, hormone replacement (other than thyroxine and contraceptive), glucoregulation.
- A hemaglobinopathy known to interfere with the ability to accurately determine HbA1c.
- No prior radiation therapy, immunotherapy, or chemotherapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: iDC recipients
iDC cells modified by in vitro engineering.
|
|
Active Comparator: Control DC recipients
DC cells which have not been modified.
|
|
Placebo Comparator: Placebo recipients
Saline injections.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The incidence of treatment-emergent adverse events.
Time Frame: Month 12
|
Month 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
2-hour area under the curve (AUC) average of C-peptide at 12 months after completion of administration of assigned therapy (Protocol Month 15).
Time Frame: 12 Months
|
12 Months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DV-0100-100
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Treatment of Type I Diabetes Mellitus.
-
Hadassah Medical OrganizationOramed Pharmaceutical Inc.CompletedBrittle Type I Diabetes MellitusIsrael
-
Nemours Children's ClinicThrasher Research FundCompleted
-
Johns Hopkins Bloomberg School of Public HealthMassachusetts General Hospital; Mayo Clinic; National Institute of Diabetes and... and other collaboratorsNot yet recruitingGastroparesis | Gastro-Intestinal Disorder | Gastroparesis Due to Diabetes Mellitus Type I | Gastroparesis Nondiabetic | Gastroparesis Due to Diabetes Mellitus Type II | Functional Disorder of Gastrointestinal TractUnited States
-
Centre d'Etudes et de Recherche pour l'Intensification...CompletedDiabetes Mellitus, Type I | Adjustment of Basal Insulin Flow Rate During Physical Activity | Adjustment of Prandial Insulin in Case of Physical ActivityFrance
-
Medtronic Diabetes R&D DenmarkUnknownDiabetes Mellitus Type II | Diabetes Mellitus Type IDenmark
-
Northwestern UniversityUniversity of Illinois at ChicagoCompletedDiabetes Mellitus Type II | Diabetes Mellitus Type IUnited States
-
Seoul National University HospitalMerck Sharp & Dohme LLCUnknownType 2 Diabetes Mellitus Without Insulin TreatmentKorea, Republic of
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
HealthPartners InstituteInternational Diabetes Center at Park Nicollet; Park Nicollet Foundation; Melrose...TerminatedEating Disorder | Type I Diabetes Mellitus Without ComplicationUnited States
-
Yanbing LiNot yet recruitingEfficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients | Metformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect | 128 Patients Were Randomly Assigned 1:1 | Metformin and Insulin Glargine Combined... and other conditionsChina
Clinical Trials on Biological
-
AstraZenecaActive, not recruiting
-
Istituto Ortopedico RizzoliCompleted
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingBrain Tumor | Brain Lesion (General)France
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
Centre Hospitalier Universitaire de NīmesCompleted
-
University Hospital, ToursRecruitingAcute Lymphoid Leukemia | Acute Myeloid Leukemia in ChildrenFrance
-
Imagine InstituteReference center for rare diseases (Rare Gynecologic Diseases)RecruitingMayer Rokitansky Kuster Hauser SyndromeFrance
-
Aibin Liang,MD,Ph.D.CARsgen Therapeutics Co., Ltd.RecruitingRelapsed and/or Refractory Multiple Myeloma | Plasma Cell Leukemia in RelapseChina
-
Centre Hospitalier Sud FrancilienCompletedFungal Infection | Bronchopulmonary Dysplasia | Extreme PrematurityFrance
-
New York Stem Cell Foundation Research InstituteSilverstein FoundationRecruitingHealthy | Parkinson Disease | Gaucher Disease | GBA Gene MutationUnited States